Cyanopyrroles
US6407101B1 · kind B1 · utility
Assignees
Inventors
Key dates
| Filing date | Apr 19, 2000 |
| Grant date | Jun 18, 2002 |
| Priority date | — |
| Expiry date | Apr 19, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D413/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides a progesterone receptor antagonist of formula 1 having the structure wherein T is O, S, or absent; R1, and R2 are each, independently, hydrogen, alkyl, substituted alkyl; or R1 and R2 are taken together form a ring and together contain —CH2(CH2)nCH2—, —CH2CH2CMe2CH2CH2—, —O(CH2)pCH2—, —O(CH2)qO—, —CH2CH2OCH2CH2—, or —CH2CH2NR7CH2CH2—;n=1-5; p=1-4; q=1-4;R3 is hydrogen, OH, NH2, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, or CORA;RA is hydrogen, alkyl, substituted alky, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;R4 is hydrogen, halogen, CN, NH2, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;R5 is hydrogen, allyl, or substituted alkyl;R6 is hydrogen, alkyl, substituted alkyl, or CORB;RB is hydrogen, alkyl, substituted alkyl, alko, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;R7 is hydrogen or alkyl; or a pharmaceutically acceptable salt thereof
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.